TP53 and non-small cell lung carcinoma: Although TP53 mutation has been associated as a negative prognostic marker with poorer overall survival in advanced NSCLC, currently TP53 deletions and oncogenic mutations are classified by OncoKB as prognostic level of evidence only for hematologic malignancies (Jiao et al., 2018).